Quantcast
Channel: Bloomberg View
Browsing all 79 articles
Browse latest View live

Fresh Market Buyout Isn't All That Appetizing

The case for a Fresh Market buyout has got some mold on it.

View Article



Team Health Wins By Waiting

Team Health was smart to hold out for more.

View Article

Hillary Clinton Doesn't Like Insurance Mergers. So What?

Her get-tough message on mega-mergers won't amount to much.

View Article

Without Malone, Vodafone Faces an Empty Dance Card

The European mobile phone giant needs a partner, but one of its best options is looking elsewhere.

View Article

Duke Has Bubblicious Feelings for Piedmont

The utility sector is paying dearly for growth.

View Article


Atmel's Clouds Have a Silver Lining

The semiconductor takeover target stands to bounce back from its two-day plunge.

View Article

Carl Icahn Has a Point About AIG

The activist's call for a breakup of the insurance behemoth makes sense.

View Article

Allergan Isn't Pfizer's Best Option

It's pricey and Pfizer can't count on tax benefits. AbbVie or Glaxo could serve instead.

View Article


Gravity-Defying Chip Bids Evoke a Bubble

A bidding war among semiconductor makers is the latest sign of froth in the M&A market.

View Article


Fresh Market Buyout Isn't All That Appetizing

The case for a Fresh Market buyout has got some mold on it.

View Article

Team Health Wins By Waiting

Team Health was smart to hold out for more.

View Article

Hillary Clinton Doesn't Like Insurance Mergers. So What?

Her get-tough message on mega-mergers won't amount to much.

View Article

Without Malone, Vodafone Faces an Empty Dance Card

The European mobile phone giant needs a partner, but one of its best options is looking elsewhere.

View Article


Duke Has Bubblicious Feelings for Piedmont

The utility sector is paying dearly for growth.

View Article

Atmel's Clouds Have a Silver Lining

The semiconductor takeover target stands to bounce back from its two-day plunge.

View Article


Carl Icahn Has a Point About AIG

The activist's call for a breakup of the insurance behemoth makes sense.

View Article

Allergan Isn't Pfizer's Best Option

It's pricey and Pfizer can't count on tax benefits. AbbVie or Glaxo could serve instead.

View Article


Gravity-Defying Chip Bids Evoke a Bubble

A bidding war among semiconductor makers is the latest sign of froth in the M&A market.

View Article

Fresh Market Buyout Isn't All That Appetizing

The case for a Fresh Market buyout has got some mold on it.

View Article

Team Health Wins By Waiting

Team Health was smart to hold out for more.

View Article
Browsing all 79 articles
Browse latest View live




Latest Images